AI-designed cancer treatment for a dog in Australia has attracted global attention after an owner used artificial intelligence tools to help develop an experimental therapy for his pet.
Paul Conyngham turned to AI after his dog Rosie was diagnosed with mast cell cancer. Her illness was first misdiagnosed as a minor issue, but a later biopsy in 2024 confirmed terminal cancer.
Conyngham initially tried conventional options, including chemotherapy, surgery, and immunotherapy. As treatment costs increased and medical options narrowed, he began exploring alternative approaches.
He used AI platforms, including ChatGPT and other tools, to research advanced cancer therapies and emerging treatments such as mRNA vaccines. He held repeated consultations with AI systems to understand scientific papers and specialist terminology.
Conyngham also paid for genome sequencing of Rosie and used AI to analyse her DNA data. That analysis helped identify potential treatment targets in her tumour.
A single operator with a chatbot just outmaneuvered the entire pharmaceutical discovery pipeline.
Australian tech entrepreneur Paul Conyngham cured his dog’s cancer.
No biology background.
Three thousand dollars.
ChatGPT and AlphaFold.
Conyngham: “We took her tumor, we… pic.twitter.com/NoYE533mKc
— Dustin (@r0ck3t23) March 15, 2026To deepen his research, he turned to AlphaFold, an AI model known for predicting protein structures. This allowed him to examine specific genetic mutations linked to Rosie’s cancer and to explore how a tailored therapy might work.
He later collaborated with researchers at the University of New South Wales. They helped turn the experimental idea into a practical treatment plan, combining his AI-assisted research with scientific oversight.
In December, Rosie received a personalised mRNA vaccine alongside immunotherapy. According to Conyngham, the AI cancer treatment for his dog reduced the size of her tumours and improved her mobility.
Experts caution that Rosie’s improvement does not amount to a confirmed cure. Instead, they describe the case as an early example of how AI, genome sequencing, and RNA-based therapies could support future cancer research.
Specialists also stress that artificial intelligence cannot replace medical judgment. Human expertise, clinical trials, and regulatory approval remain essential before any AI-designed cancer treatment for dogs or humans can become standard care.
The process required navigating ethical approvals and research protocols. Conyngham says AI tools assisted with drafting documentation and managing some of the complex requirements, but human review came first.
In the end, the story reflects both technological potential and personal determination. AI played a key role in guiding research, but the outcome depended on collaboration with scientists and sustained effort from Rosie’s owner.
Rosie’s case continues to fuel debate about the future of AI-assisted healthcare and personalised treatments for both pets and people. It also raises questions about access, safety, and how regulators will oversee AI-driven therapies.
